Fumarate compounds, pharmaceutical compositions thereof, and methods of use

A compound according to Formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• R1 is selected from the group consisting of hydrogen, C1-6 alkyl, substituted C1-6 alkyl, C1-6 heteroalkyl, substituted C1-6 heteroalkyl, C3-12 cycloalkyl, substituted C3-12 cycloalkyl, C3-12 heterocycloalkyl, substituted C3-12 heterocycloalkyl, C5-10 aryl, substituted C5-10 aryl, C5-10 heteroaryl, and substituted C5-10 heteroaryl;
• R2 and R3 together with the carbon to which they are bonded form a (2,4-dioxo-1H-pyrimidin-5-yl) ring;
• and
• X1 and X2 are independently selected from the group consisting of a bond and C1-6 alkane-diyl;
• wherein each substituent group is independently selected from the group consisting of halogen, —OH, —CN, —CF3, ═O, —NO2, benzyl, —C(O)NR212, —R21, —OR21, —C(O)R21, —C(O)OR21, —NR212, —NR21C(O)R21, and —O(O)R21, wherein each R21 is independently selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 heteroalkyl, C3-12 cycloalkyl, C5-10 aryl, C5-10 heteroaryl, and amino acid side chain.